Kamal Hamed

Kamal Hamed

Auto-generated profile, based on publicly available information

Kamal Hamed

Spero Therapeutics, Inc., Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2013 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ATAlfred B Tiono
Alfred B Tiono
AOAlphonse Ouédraogo
Alphonse Ouédraogo
BOBernhards Ogutu
Bernhards Ogutu
ADAmidou Diarra
Amidou Diarra
SCSam Coulibaly
Sam Coulibaly
KHKamal Hamed
Kamal Hamed
In malaria-endemic countries, large proportions of infected individuals are asymptomatic, constituting a reservoir of parasites for infection of newly hatched mosquitoes. This study evaluated the impact of screening and treatment of asymptomatic carriers of Plasmodium falciparum.

12 October 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
THThomas L. Holland
Thomas L. Holland
SCSara E. Cosgrove
Sara E. Cosgrove
SDSarah B. Doernberg
Sarah B. Doernberg
TJTimothy C. Jenkins
Timothy C. Jenkins
NTNicholas A. Turner
Nicholas A. Turner
VFVance G. Fowler
Vance G. Fowler
Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus. In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new S. aureus bacteremia-related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments. Safety was also assessed. Of 390 patients who underwent randomization, 387 (189 in the ceftobiprole group and 198 in the daptomycin group) had confirmed S. aureus bacteremia and received ceftobiprole or daptomycin (modified intention-to-treat population). A total of 132 of 189 patients (69.8%) in the ceftobiprole group and 136 of 198 patients (68.7%) in the daptomycin group had overall treatment success (adjusted difference, 2.0 percentage points; 95% confidence interval [CI], -7.1 to 11.1). Findings appeared to be consistent between the ceftobiprole and daptomycin groups in key subgroups and with respect to secondary outcomes, including mortality (9.0% and 9.1%, respectively; 95% CI, -6.2 to 5.2) and the percentage of patients with microbiologic eradication (82.0% and 77.3%; 95% CI, -2.9 to 13.0). Adverse events were reported in 121 of 191 patients (63.4%) who received ceftobiprole and 117 of 198 patients (59.1%) who received daptomycin; serious adverse events were reported in 36 patients (18.8%) and 45 patients (22.7%), respectively. Gastrointestinal adverse events (primarily mild nausea) were more frequent with ceftobiprole. Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S. aureus bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.).

1 January 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FAFred Y. Aoki
Fred Y. Aoki
STStephen Tyring
Stephen Tyring
FDFrancisco Diaz-Mitoma
Francisco Diaz-Mitoma
GGGerd Gross
Gerd Gross
JGJoseph Gao
Joseph Gao
KHKamal Hamed
Kamal Hamed
Background. Orally administered antiviral therapy for genital herpes improves the time to lesion healing and resolves symptoms during an outbreak. Al

1 June 2020 in Medical Mycology
Verified
Journal Article
Open access
PDF file
SSStefan Schwartz
Stefan Schwartz
OCOliver A. Cornely
Oliver A. Cornely
KHKamal Hamed
Kamal Hamed
FMFrancisco M Marty
Francisco M Marty
JMJohan Maertens
Johan Maertens
WHWerner J Heinz
Werner J Heinz
The incidence of invasive fungal diseases (IFDs) with central nervous system (CNS) involvement is increasing due to the rising numbers of immunocompromised individuals, such as patients receiving chemotherapy, transplantation procedures, or immune-modulating therapies. CNS IFDs cause significant morbidity and mortality, and treatments are complicated by difficulties in identifying fungal pathogens and delivering antifungal agents to the CNS. Isavuconazole is a novel triazole with broad-spectrum activity that has shown good blood–brain barrier penetration in animal models. We present a retrospective analysis of isavuconazole in the treatment of patients with CNS IFDs and who either participated in the phase III VITAL or SECURE clinical trials, or were included in a named-patient program. A total of 36 patients were identified, including 27 patients from the clinical trials. Of these patients, 47.2% had hematologic malignancies, while 13.9% had no identifiable underlying conditions. Mucorales, Aspergillus species, and Cryptococcus species accounted for 30.6%, 22.2%, and 13.9% of infections, respectively. The overall survival rate was 80.6% at day 42 and 69.4% at day 84, and at the end of treatment, a complete or partial clinical response was achieved in 58.3% of patients. Isavuconazole exhibited clinical activity in a variety of CNS IFDs.

2 December 2012 in Malaria Journal
Verified
Journal Article
Open access
PDF file
UDUmberto D'Alessandro
Umberto D'Alessandro
DUDavid Ubben
David Ubben
KHKamal Hamed
Kamal Hamed
SCSerign Jawo Ceesay
Serign Jawo Ceesay
JOJoseph Okebe
Joseph Okebe
BBBernard Brabin
Bernard Brabin
Despite the protection provided by several factors, including maternal antibodies, the burden of malaria in young infants may be higher than previously thought. Infants with congenital or neonatal malaria may have a different clinical presentation than older children, and diagnosis may be confused with other neonatal diseases due to an overlap of clinical manifestations. In addition, there is little information on the use of artemisinin-based combination therapy in young infants. There is the need for a more accurate estimate of the parasite prevalence and the incidence of clinical malaria in infants under 6 months old, as well as a better characterization of risk factors, pharmacokinetic profiles, safety and efficacy of currently available anti-malarial treatments, in order to develop evidence-based treatment guidelines for this population.

7 August 2012 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
FVFidel Villegas
Fidel Villegas
RARené Angles
René Angles
RBRené Barrientos
René Barrientos
GBGary Barrios
Gary Barrios
M. Adela ValeroM. Adela Valero
M. Adela Valero
AGAlbis Francesco Gabrielli
Albis Francesco Gabrielli
The Bolivian northern Altiplano is characterized by a high prevalence of Fasciola hepatica infection. In order to assess the feasibility, safety and efficacy of large-scale administration of triclabendazole as an appropriate public health measure to control morbidity associated with fascioliasis, a pilot intervention was implemented in 2008. Schoolchildren from an endemic community were screened for fascioliasis and treated with a single administration of triclabendazole (10 mg/kg). Interviews to assess the occurrence of adverse events were conducted on treatment day, one week later, and one month after treatment. Further parasitological screenings were performed three months after treatment and again two months later (following a further treatment) in order to evaluate the efficacy of the intervention. Ninety infected children were administered triclabendazole. Adverse events were infrequent and mild. No serious adverse events were reported. Observed cure rates were 77.8% after one treatment and 97.8% after two treatments, while egg reduction rates ranged between 74% and 90.3% after one treatment, and between 84.2% and 99.9% after two treatments. The proportion of high-intensity infections (≥400 epg) decreased from 7.8% to 1.1% after one treatment and to 0% after two treatments. Administration of triclabendazole is a feasible, safe and efficacious public health intervention in an endemic community in the Bolivian Altiplano, suggesting that preventive chemotherapy can be applied to control of fascioliasis. Further investigations are needed to define the most appropriate frequency of treatment. Fascioliasis is highly prevalent in the northern Altiplano of Bolivia. We wanted to ascertain whether a preventive chemotherapy approach, involving the large-scale distribution of triclabendazole within endemic communities, would be feasible for controlling morbidity associated with this disease. Consequently, we implemented a pilot intervention among schoolchildren in a community near Lake Titicaca and assessed this intervention's safety (by evaluating the occurrence of adverse events following treatment) and its efficacy (by measuring changes in prevalence and intensity of infection). Adverse events on treatment day, and one week and one month later were infrequent and mild, and no serious adverse events were reported. We observed cure rates of 77.8% after one treatment and 97.8% after two treatments, egg reduction rates of 74–90.3% after one treatment and 84.2–99.9% after two treatments, and a decrease in the proportion of high-intensity infections (≥400 epg) from 7.8% to 1.1% after one treatment and to 0% after two treatments. We conclude that administration of triclabendazole is a safe and efficacious public health intervention for control of fascioliasis in an endemic community in the Bolivian Altiplano. Preventive chemotherapy with triclabendazole, without individual-level diagnosis and treatment, appears therefore as a feasible option. However, further investigation is needed to define the most appropriate frequency of treatment.